


VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on October 6, 2000

FULBRIGHT & JAWORSKI L.L.P.

UD 5253.5 DIV (09885911)

AF
1644



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Thierry BOON-FALLEUR et al.
Serial No. : 08/819,669
Filed : March 17, 1997
For : TUMOR REJECTION ANTIGEN PRECURSORS,
TUMOR REJECTION ANTIGENS AND USES
THEREOF
Art Unit : 1644
Examiner : P. Gamble

October 6, 2000

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

RECEIVED

OCT 12 2000

TECH CENTER 1600/2900

**AMENDMENT
UNDER 37
CFR § 1.116**

This amendment is responsive to the office action dated September 26, 2000. Please amend applications as follows:

IN THE SPECIFICATION

Page 27, next to last line: change "Balb/C" to - - BALB/c - -

Page 28, line 3: change "BALB/C" to - - BALB/c - -

IN THE CLAIMS

Amend claim 176 as follows:

Claim 176 (amended)

The isolated tumor rejection antigen precursor of claim 174, wherein said tumor rejection antigen precursor is encoded by a nucleic acid molecule, the complementary nucleotide sequence of which hybridizes to SEQ ID NO: 8 [, under stringent conditions] at 0.1XSSC, 0.1% SDS.